Trial Profile

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Azathioprine; Cyclophosphamide; Prednisone
Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
Focus Registrational; Therapeutic Use
Acronyms MAINRITSAN

Most Recent Events

02 Nov 2023 Results of pooled analysis from MAINRITSAN, MAINRITSAN 2 and MAINRITSAN 3, published in the Annals of the Rheumatic Diseases
14 Nov 2022 Results of pooled analysis assessing long term outcome using data from MAINRITSAN trials, presented at the ACR Convergence 2022.
06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com